Literature DB >> 31404524

LncRNA AK094457 promotes AngII-mediated hypertension and endothelial dysfunction through suppressing of activation of PPARγ.

Xiaozhen Zhuo1, Yan Wu1, Yanjie Yang1, Li Gao1, Xiangrui Qiao1, Tao Chen2.   

Abstract

Hypertension is one of the major risk factors for cardiovascular disease worldwide and is striking more young people, which is characterized by impaired vascular endothelial function. To find the functional lncRNAs associated with hypertension, high throughput lncRNA microarray were used to analyze expression profile of the lncRNAs in the aortic vascular endothelial cells (VECs) of spontaneously hypertensive rats (SHRs). The tail vein injection of siRNA was used to study the influence of lncRNA AK094457 inhibition on endothelial function in vivo. In vitro, endothelial function was studied in endothelial cells transfected with lncRNA AK094457-overexpressed vectors and siRNAs. pPPARγ and iNOS protein levels were detected with Western blot. Elisa assay was used to analyze the secretion of AngII, ET-1, ROS and LDH level. The nitrite/nitrate (NO2-/NO3-) concentration was measured using a colorimetric assay. LncRNA AK094457 was a most upregulated lncRNA in SHRs. It is showed that downregulation of AK094457 significantly reduced rat arterial pressure, increased activation of endothelial PPARγ, and suppressed serum contents of AngII and NO in vivo. Furthermore, results from gain-and-loss of function in primary aortic endothelial cells indicated that AK094457 negatively regulated activation of PPARγ and promoted AngII-mediated endothelial dysfunction, manifested by decreased capacities of cell proliferation and migration, and increased levels of ROS production and LDH release. In conclusion, lncRNA AK094457 is identified as a key regulator in blood pressure and endothelial function, which can increase AngII-induced hypertension and endothelial dysfunction via suppression of PPARγ.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AngII; Endothelial dysfunction; Hypertension; LncRNA AK094457; PPARγ

Mesh:

Substances:

Year:  2019        PMID: 31404524     DOI: 10.1016/j.lfs.2019.116745

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

Review 1.  Long non-coding RNAs: a valuable biomarker for metabolic syndrome.

Authors:  Mohammad Rashidmayvan; Reza Sahebi; Majid Ghayour-Mobarhan
Journal:  Mol Genet Genomics       Date:  2022-07-19       Impact factor: 2.980

2.  Knockdown of Long Noncoding RNA (lncRNA) AK094457 Relieved Angiotensin II Induced Vascular Endothelial Cell Injury.

Authors:  JiaYi Xu; Yingjie Sun; Jie Lu
Journal:  Med Sci Monit       Date:  2020-02-06

Review 3.  Long non-coding RNAs as biomarkers and therapeutic targets for ischemic stroke.

Authors:  Galina Sufianova; Alina Shumadalova; Yao Wenhao; Ilgiz Gareev
Journal:  Noncoding RNA Res       Date:  2022-09-10

4.  LncRNA and mRNA expression profiles and functional networks of hyposalivation of the submandibular gland in hypertension.

Authors:  Zhu-Jun Shen; Ye-Chen Han; Yi-Ning Wang; Hong-Zhi Xie
Journal:  Sci Rep       Date:  2020-08-18       Impact factor: 4.379

5.  Berberine ameliorates vascular dysfunction by a global modulation of lncRNA and mRNA expression profiles in hypertensive mouse aortae.

Authors:  Na Tan; Yi Zhang; Yan Zhang; Li Li; Yi Zong; Wenwen Han; Limei Liu
Journal:  PLoS One       Date:  2021-02-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.